|
|
Office Locations:
|
40 West 57th Street, 28th Floor
New York, NY 10019
Phone: 212-247-6400
| | |
|
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
|
Access Biotechnology invests in transformative therapies for conditions with high unmet needs and that have the potential to meaningfully impact human health. Access is the Life Sciences investment division of Access Industries (see profile), which is the investment platform for Len Blavatnik. Len Blavatnik is a global industrialist and philanthropist with over 33 years of experience in deploying long-term capital. In 1986, Mr. Blavatnik founded Access Industries, a privately-held industrial group based in the U.S. Access owns strategic and diversified investments around the world in media and entertainment, natural resources and commodities, real estate, venture capital, and biotechnology. Access Bio invests in both private and public biopharma companies across therapeutic areas, modalities, and development stages -- from discovery-stage technology platforms to late-stage clinical programs.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
